Alembic receives USFDA final approval for Nifedipine Extended-Release Tablets
Nifedipine Extended-Release Tablets have an estimated market size of US $56 million for twelve months ending September 2022
Nifedipine Extended-Release Tablets have an estimated market size of US $56 million for twelve months ending September 2022
LHWRF will work with the State’s Department of Health and Family Welfare for strengthening the healthcare system and addressing the prevalence of CVD and COPD for better outcomes
Acquisition expands Merck’s growing hematology portfolio
The newly built complex of RRIUM, which will be under CCRUM, the apex government organization for research in Unani Medicine
The product is expected to be launched by Q4 FY23.
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
India is home to nearly 80 million diabetics and this number is expected to rise to a staggering 134 million in the next 25 years.
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Cyclophosphamide Capsules, 25 mg and 50 mg, have an estimated market size of US$ 8 million for twelve months ending Sep 2022 according to IQVIA.
The company is making its entry into the Hyderabad market through its unique asset-light business model
Subscribe To Our Newsletter & Stay Updated